Sanyou Biopharmaceuticals officially launched its independently developed Super-Trillion Antibody Libraries (STAL) recently, and the concomitant innovative antibody drug discovery platform. Established by Sanyou after seven years of continuous innovation and independent R&D, the STAL antibody drug discovery platform represents a significant breakthrough over the previous generation of the sub-trillion innovative antibody discovery platforms.

"There were a lot of requirements for drug innovation from companies of my friends in the community, and our team had marketing experiences. Therefore, we were sure we could make ends meet," Guojun Lang, CEO, Sanyou, said.

With the technology, contracts, and people willing to join, Dr. Lang, together with two friends, founded Sanyou Biopharmaceuticals in 2015.

"The team of three in the first year of establishment grew to 10 members in the second year, 27 in the third year, 50 in the fourth year." He clearly counted the number of staffs in every step of Sanyou's development.

At the beginning of 2019, Sanyou initiated its plan for the construction of trillion-level antibody libraries. The first trillion-level antibody library was actually completed in December 2020, but what Sanyou planned to establish was a series of trillion-level libraries, rather than only one trillion antibody library.

"Now we have five trillion-level antibody libraries, with a large library capacity of seven trillion in total." After 7 years of upgrading for three generations, the property and performance of Sanyou's super-trillion antibody libraries are showing international advantages.